.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,296,504

« Back to Dashboard

Claims for Patent: 5,296,504

Title: Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
Abstract:The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.
Inventor(s): Stjernschantz; Johan W. (Uppsala, SE), Resul; Bahram (Uppsala, SE)
Assignee: Kabi Pharmacia (SE)
Application Number:07/987,520
Patent Claims: 1. A therapeutic composition for topical treatment of ocular hypertension comprising 13,14-dihydro-17-phenyl-18,19,20-trinor PGF2.alpha. isopropyl ester in an amount sufficient to reduce intraocular pressure without causing substantial ocular irritation, and an ophthalmologically compatible vehicle.

2. The therapeutic composition of claim 1 in which the ophthalmologically compatible vehicle comprises a solubilizing agent.

3. A therapeutic composition for topical treatment of ocular hypertension comprising 13,14-dihydro-17-phenyl-18,19,20-trinor PGF2.alpha. isopropyl ester in an amount sufficient to reduce intraocular pressure without causing substantial ocular irritation, and an ophthalmologically compatible vehicle comprising an aqueous saline solution containing benzalkonium chloride.

4. A method of treating ocular hypertension by topical application of the therapeutic composition of claim 1.

5. The method of claim 4 in which the composition of claim 1 is applied once or twice a day.

6. The method of claim 4 wherein the composition applied contains from about 0.1 .mu.g to about 30 .mu.g of 13,14-dihydro-17-phenyl-18,19,20-trinor PGF2.alpha. isopropyl ester.

7. The method of claim 4 wherein the composition applied contains about 1.0 .mu.g to about 10 .mu.g of 13,14-dihydro-17-phenyl-18,19,20-trinor PGF2.alpha. isopropyl ester.

8. The method of claim 4 wherein the composition is applied twice a day, containing about 1.0 .mu.g to about 10 .mu.g of prostaglandin in a volume of about 10 to about 50 .mu.L of composition.

9. A therapeutic composition for topical treatment of glaucoma comprising 13,14-dihydro-17-phenyl-18,19,20-trinor PGF2.alpha. isopropyl ester in an amount sufficient to reduce intraocular pressure without causing substantial ocular irritation, and an ophthalmologically compatible vehicle.

10. The therapeutic composition of claim 9 in which the ophthalmologically compatible vehicle comprises a solubilizing agent.

11. A therapeutic composition for topical treatment of glaucoma comprising 13,14-dihydro-17-phenyl-18,19,20-trinor PGF2.alpha. isopropyl ester in an amount sufficient to reduce intraocular pressure without causing substantial ocular irritation, and an ophthalmologically compatible vehicle comprising an aqueous saline solution containing benzalkonium chloride.

12. A method of treating glaucoma by topical application of the therapeutic composition of claim 9.

13. The method of claim 12 in which the composition of claim 9 is applied once or twice a day.

14. The method of claim 12 wherein the composition applied contains from about 0.1 .mu.g to about 30 .mu.g of 13,14-dihydro-17-phenyl-18,19,20-trinor PGF2.alpha. isopropyl ester.

15. The method of claim 12 wherein the composition applied contains about 1.0 .mu.g to about 10 .mu.g of 13,14-dihydro-17-phenyl-18,19,20-trinor PGF2.alpha. isopropyl ester.

16. The method of claim 12 wherein the composition is applied twice a day, containing about 1.0 .mu.g to about 10 .mu.g of prostaglandin in a volume of about 10 to about 50 .mu.L of composition.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc